Company Filing History:
Years Active: 2020-2022
Title: Innovations by Pavel Vereshchetin in Diabetes Management
Introduction
Pavel Vereshchetin is a notable inventor based in Moscow, Russia, recognized for his contributions to diabetes management technology. With a total of three patents to his name, Vereshchetin has developed innovative systems aimed at improving the quality of life for individuals with diabetes.
Latest Patents
One of his latest patents is focused on maintaining maximum dosing limits for closed-loop insulin management systems. This system includes an infusion pump, glucose sensor, and a controller programmed to manage insulin delivery based on stored variables. The controller calculates a maximum insulin delivery rate by considering various factors such as the default basal insulin delivery rate and temporary basal insulin delivery rate.
Another significant patent by Vereshchetin involves insulin-on-board accounting in an artificial pancreas system. This system integrates a continuous glucose monitoring device with a drug delivery device that exchanges data and contains a control algorithm. The algorithm is designed to calculate two versions of insulin-on-board, ensuring accurate management of insulin intended for high glucose correction.
Career Highlights
Throughout his career, Pavel Vereshchetin has worked with prominent companies in the healthcare technology sector, including Lifescan IP Holdings and Lifespan IP Holdings. His work has significantly impacted the development of diabetes management solutions, showcasing his expertise in the field.
Collaborations
Vereshchetin has collaborated with various professionals, including Daniel Finan, to enhance the effectiveness of his inventions and contribute to advancements in diabetes care.
Conclusion
Pavel Vereshchetin's innovative patents and career achievements highlight his dedication to improving diabetes management through technology. His work continues to influence the field and offers hope for better health outcomes for individuals living with diabetes.